Satisfaction with glucose-lowering treatment and well-being in patients with type 2 diabetes and myocardial infarction: A DIGAMI2 QoL sub-study

• Published in: Diabetes & vascular disease research Vol. 10; no. 3; pp. 263 - 269
• Main Authors: Venskutonyte, Laura, Brismar, Kerstin, Rydén-Bergsten, Tina, Rydén, Lars, Kjellström, Barbro
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.05.2013
• Subjects: Administration, Oral; Aged; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; Diabetic Angiopathies - epidemiology; Diabetic Cardiomyopathies - epidemiology; Endokrinologi och diabetes; Female; Follow-Up Studies; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Insulin - adverse effects; Insulin - therapeutic use; Kardiologi; Klinisk medicin; Male; Medicin och hälsovetenskap; Middle Aged; Myocardial Infarction - complications; Myocardial Infarction - epidemiology; Patient Satisfaction; Quality of Life; Risk Factors; Surveys and Questionnaires; Sweden - epidemiology; Sweden; type 2 diabetes; treatment satisfaction; insulin treatment; Quality of life
• ISSN: 1479-1641; 1752-8984; 1752-8984
• DOI: 10.1177/1479164112463711

The second Diabetes Glucose and Myocardial Infarction (DIGAMI 2) study randomised patients with diabetes and myocardial infarction to insulin or oral-based treatment. To determine the effects of insulin-based treatment, the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Psychological General Well-Being (PGWB) Index were administered at baseline and 12 months. Insulin-treated patients (n = 197) had a worse risk profile and more co-morbidity at baseline than patients on oral glucose-lowering agents (n = 127). The treatment satisfaction and psychological well-being was similar between insulin and oral groups at baseline [DTSQ: median (first–third quartile) 30 (24–34) vs 31 (27–34), NS; PGWB: 77 (73–82) vs 79 (76–82), NS] and at 12 months [DTSQ: 32 (28–35) vs 34 (30–36), NS; PGWB: 81 (78–84) vs 82 (78–84), NS]. Improvement was significant in both groups. Insulin-based therapy was well accepted and did not decrease treatment satisfaction or psychological well-being compared to oral glucose-lowering treatment in patients with type 2 diabetes and myocardial infarction.